Kerbiriou L, Ustianowski A, Johnson M A, Gillespie S H, Miller R F, Lipman M C I
Department of Respiratory Medicine, Royal Free Hospital, London, United Kingdom.
Clin Infect Dis. 2003 Nov 1;37(9):1250-4. doi: 10.1086/378806. Epub 2003 Oct 7.
We report treatment decisions and outcomes for 20 patients who were infected with human immunodeficiency virus type 1 (HIV-1) and were receiving highly active antiretroviral therapy (HAART) who had respiratory symptoms and from whom Mycobacterium xenopi was isolated. All patients also had coexisting pulmonary pathologic conditions. The median blood T cell CD4 count was 37 cells/microL (range, 2-480 cells/microL). Fifteen of 20 patients received no antimycobacterial therapy and remain healthy after a median of approximately 4 years of follow-up, and 2 patients required treatment specifically for M. xenopi infection, both showing clinical improvement. We conclude that pulmonary M. xenopi isolation in HIV-1 patients receiving HAART does not usually require specific treatment.
我们报告了20例感染1型人类免疫缺陷病毒（HIV-1）并接受高效抗逆转录病毒治疗（HAART）且出现呼吸道症状并分离出偶发分枝杆菌的患者的治疗决策和结果。所有患者还并存肺部病理状况。血液T细胞CD4计数中位数为37个细胞/微升（范围为2 - 480个细胞/微升）。20例患者中有15例未接受抗分枝杆菌治疗，经过约4年的中位随访后仍保持健康，2例患者需要针对偶发分枝杆菌感染进行治疗，两者均显示出临床改善。我们得出结论，在接受HAART的HIV-1患者中，肺部分离出偶发分枝杆菌通常不需要特殊治疗。
